Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00152555
Other study ID # 13238B
Secondary ID
Status Terminated
Phase N/A
First received September 8, 2005
Last updated June 11, 2013
Start date March 2003
Est. completion date March 2007

Study information

Verified date April 2007
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see if there is an improvement in patient's quality of life, pain, and fatigue after undergoing a supervised exercise program. If improvement is found, this will help guide standard of care with lupus patients with a focus on exercise for improvement of endurance, pain and overall health.


Description:

After patients have been selected and consented for this study, they will fill out a series of questionnaires. These surveys are used to stratify the patient's disease activity, assess perception of disease limitations including quality of life, fatigue and pain. We intend to use the Systemic Lupus Disease Activity Index (SLEDAI) to quantify disease activity and the SLICC to characterize the study population.

Pain, fatigue and depression will be assessed with the Pain Visual analogue scale, Fatigue Severity Score (FSS), Patient Global Assessment and BECK depression scale. Other initial data to be collected include patient's prednisone dose and resting heart rate. No specific laboratory data will be collected for this study. Patients will continue with standard of care monitoring based on their disease activity and medications.

The 100 patients will be randomized approximately 50 in the exercise group and 50 in the relaxation therapy group. The relaxation group will serve as the control arm of the study. The patients in the relaxation therapy group will then undergo a training session on biofeedback as well as receive further materials on relaxation techniques and a relaxation tape. The relaxation tape will request subjects to systematically contract and relax eleven isolated muscle groups. These muscle groups include; hands and wrists, biceps and triceps, shoulders alone, neck, tongue and mouth, eyes, nose and forehead, back alone, abdominal area alone, thighs alone, calves and feet and finally toes alone. This group of subjects will be asked to perform relaxation exercises at home a minimum of three times a week.

The subjects in the exercise group will have visits about 2 times per week for a total of 8 weeks, for a total of 16 visits. The first visit will include a general evaluation (strength, range of motion, standing balance, gait assessment, baseline vitals), determination of heart rate range for exercise and explanation of exercise portion of the study and home exercise program. Visits 2 through 16 you will participate in simple, supervised exercise at the physical therapy center at the University of Chicago. Heart rates will be measured several times throughout your exercise visits. Additionally, subjects will be asked to rate your level of pain, your blood pressure will be taken before and after and you will be advised regarding at home exercises.

Each subject will be seen for 16 visits total, unless a he/she stops attending PT sessions on their own.


Recruitment information / eligibility

Status Terminated
Enrollment 100
Est. completion date March 2007
Est. primary completion date March 2007
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

Diagnosis of SLE by ACR criteria; Age 16+ -

Exclusion Criteria:

patients with an active lupus flare, or patients with physical limitations impairing their ability to participate in physical therapy. Other groups that will be excluded are those with limiting pulmonary disease and coronary artery disease. Patients with mechanical or structural abnormalities that would prohibit exercise (i.e. avascular necrosis of a weight-bearing joint) will also be excluded. Finally, patients already participating in a regular exercise program (>1 day per week), or those with other conditions (based on the physicians discretion) which prohibit participating in physical therapy will not qualify for this study.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Physical Therapy or Relaxation Therapy


Locations

Country Name City State
United States University of Chicago Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome measure is to assess quality of life with the SF-36 Physical Function Domain.
Secondary Pain, fatigue and depression assessed with the Pain Visual analogue scale, Fatigue Severity Score (FSS), Patient Global Assessment and BECK depression scale.
See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Recruiting NCT05967520 - JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus Phase 2
Completed NCT02875691 - Effect of Green Tea on Treatment of Lupus Phase 2
Completed NCT02922114 - Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients N/A
Withdrawn NCT01702038 - Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Completed NCT00065806 - Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Phase 3
Completed NCT00005436 - Lupus Cohort--Thrombotic Events and Coronary Artery Disease N/A
Recruiting NCT03543839 - Trial of Belimumab in Early Lupus Phase 4
Completed NCT03098823 - A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Phase 4
Recruiting NCT05899907 - Efficacy and Safety of Telitacicept in Early SLE Phase 4
Completed NCT04956484 - Belimumab In Early Systemic Lupus Erythematosus Phase 4
Completed NCT05326841 - Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients . Phase 3
Completed NCT02655640 - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis N/A
Completed NCT02034344 - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Phase 0
Terminated NCT00089804 - Study of LJP 394 in Lupus Patients With History of Renal Disease Phase 3
Completed NCT00071487 - Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) Phase 2
Completed NCT02349061 - A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus Phase 2
Recruiting NCT05636670 - Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease